Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CABALETTA BIO INC (CABA) Stock Price & Overview
NASDAQ:CABA • US12674W1099
Current stock price
2.94 USD
-0.05 (-1.67%)
At close:
2.96 USD
+0.02 (+0.68%)
After Hours:
The current stock price of CABA is 2.94 USD. Today CABA is down by -1.67%. In the past month the price decreased by -0.68%. In the past year, price increased by 119.4%.
CABA Key Statistics
52-Week Range1.11 - 3.78
Current CABA stock price positioned within its 52-week range.
1-Month Range2.715 - 3.5693
Current CABA stock price positioned within its 1-month range.
- Market Cap
- 327.281M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.28
- Dividend Yield
- N/A
CABA Stock Performance
Today
-1.67%
1 Week
-0.34%
1 Month
-0.68%
3 Months
+14.40%
Longer-term
6 Months -18.56%
1 Year +119.40%
2 Years -71.15%
3 Years -70.86%
5 Years -74.07%
10 Years N/A
CABA Stock Chart
CABA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CABA. When comparing the yearly performance of all stocks, CABA is one of the better performing stocks in the market, outperforming 92.75% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CABA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CABA. CABA has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CABA Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 23, 2026
PeriodQ4 / 2025
EPS Reported-$0.40
Revenue Reported
EPS Surprise 15.63%
Revenue Surprise %
CABA Forecast & Estimates
16 analysts have analysed CABA and the average price target is 13.39 USD. This implies a price increase of 355.36% is expected in the next year compared to the current price of 2.94.
Analysts
Analysts83.75
Price Target13.39 (355.44%)
EPS Next Y29.95%
Revenue Next YearN/A
CABA Index Membership
CABA is currently included in the following stock indexes tracked on ChartMill.
CABA Financial Highlights
Over the last trailing twelve months CABA reported a non-GAAP Earnings per Share(EPS) of -2.28. The EPS increased by 2.56% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-167.86M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.68% | ||
| ROE | -149.8% | ||
| Debt/Equity | 0.03 |
Chartmill High Growth Momentum
EPS Q2Q%38.46%
Sales Q2Q%N/A
EPS 1Y (TTM)2.56%
Revenue 1Y (TTM)N/A
CABA Ownership
Ownership
Inst Owners68.51%
Shares111.32M
Float109.70M
Ins Owners1.45%
Short Float %17.9%
Short Ratio8.66
CABA Industry Overview
CABA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
CABA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CABA
Company Profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
IPO: 2019-10-25
CABALETTA BIO INC
2929 Arch Street, Suite 600
PHILADELPHIA PENNSYLVANIA 19104 US
CEO: Steven Nichtberger
Employees: 155
Phone: 13026587581
CABALETTA BIO INC / CABA FAQ
What does CABALETTA BIO INC do?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
What is the current price of CABA stock?
The current stock price of CABA is 2.94 USD. The price decreased by -1.67% in the last trading session.
What is the dividend status of CABALETTA BIO INC?
CABA does not pay a dividend.
What is the ChartMill rating of CABALETTA BIO INC stock?
CABA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is CABALETTA BIO INC worth?
CABALETTA BIO INC (CABA) has a market capitalization of 327.28M USD. This makes CABA a Small Cap stock.
What is the Short Interest ratio of CABALETTA BIO INC (CABA) stock?
The outstanding short interest for CABALETTA BIO INC (CABA) is 17.9% of its float.